Toll-like receptor signaling pathway triggered by inhibition of serpin A1 stimulates production of inflammatory cytokines by endometrial stromal cells

Kazuya Kusama1*, Ayaka Satoyoshi1, Mana Azumi1, Mikihiro Yoshie1, Junya Kojima2, Yumi Mizuno3, Masanori Ono2, Hirotaka Nishi2, Takeshi Kajihara3 and Kazuhiro Tamura1

1Department of Endocrine Pharmacology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan, 2Department of Obstetrics and Gynecology, Tokyo Medical University, Tokyo, Japan, 3Department of Obstetrics and Gynecology, Saitama Medical University, Saitama, Japan

Endometriosis is characterized by the presence of inflamed and fibrotic endometrial tissue outside the uterine cavity. Previously, we found decreased SERPINA1 (alpha-1 antitrypsin) expression in endometriosis-like lesions in a mouse model of endometriosis, suggesting that it exacerbated inflammation in these lesions. However, the molecular mechanism(s) by which SERPINA1 affects expression of inflammatory factors and development of endometriotic lesions have not been fully characterized. To investigate the role of intracellular SERPINA1 in endometrial stromal cells (ESCs), we performed RNA sequence analysis using RNA extracted from ESCs in which SERPINA1 was knocked down. The analysis identified several toll-like receptor (TLR)-related factors as being upregulated. Silencing of SERPINA1 increased expression of TLR3 and TLR4 in ESCs, as well as several TLR signaling pathway components, including MYD88, IRAK1/4, interleukin (IL)-1β, and interferon (IFN)-β. TLR3 or TLR4 agonists increased expression of inflammatory factors in SERPINA1-knockdown ESCs, whereas TLR3 or TLR4 inhibitors decreased expression. In addition, treatment with recombinant IL-1β or IFN-β increased expression of MYD88 and inflammatory factors in ESCs. Immunohistochemical analysis of endometriotic tissues showed that TLR3, TLR4, and MYD88 were localized in endometriosis lesions. Taken together, the data suggest that reduced expression of SERPINA1 induces expression of inflammatory factors by ESCs, which in turn are associated with TLR3/4, IL-1β, and IFN-β signaling. Regulation of intracellular SERPINA1 levels in ESCs may be a strategy to inhibit inflammatory responses in endometriotic lesions.

KEYWORDS
endometrial stromal cells, serpin A1, alpha-1 antitrypsin, toll-like receptor, interferon beta, interleukin-1 beta, endometriosis
**Introduction**

Endometriosis is a chronic inflammatory disease characterized by the presence of inflamed and fibrotic endometrial tissue outside the uterine cavity (1–4). The etiology of endometriotic lesions may be associated with retrograde menstruation, in which menstrual debris (including endometrial stromal and epithelial cells) flows back into the pelvic cavity through the fallopian tubes (1, 2). The attachment and transformation of endometrial cells at ectopic sites involves the development of endometriosis (4). Fibrogenesis and chronic inflammation, which are important stages in the formation of endometriotic lesions, are closely associated with severe pain. Several experimental models are available to study endometriosis and to evaluate the therapeutic benefits of different compounds. For example, in our experimental internal bleeding mouse model, distinct endometriosis-like grafts were generated near the surgical site of unilateral ovariectomy after transplantation of human endometrial cells. In endometriosis-like lesions, levels of interleukin 6 (IL-6) and prostaglandin E2 (PGE2) increased, whereas that of SERPINA1 (known as alpha-1 antitrypsin) decreased (5, 6). Treatment of endometrial stromal and glandular epithelial cells with PGE2 and thrombin significantly increases secretion of IL-6, as well as by endometriotic lesions (5, 7, 8). Notably, the IL-6 and IL-8 concentrations in the serum of patients with endometriosis are higher than those in healthy women (9, 10). Furthermore, production of PGE2 is increased in patients with endometriosis (11–14).

SERPINA1, a member of the serpin superfamily, is a serine protease inhibitor synthesized primarily by hepatocytes as an acute-phase reaction product; it is then secreted into the serum (15). On the other hand, SERPINA1 is a protein ubiquitously expressed in various cells and localized in the cytoplasm and endoplasmic reticulum. Previous studies showed that a reduction in intracellular SERPINA1 protein levels exacerbates inflammatory responses in endometriosis-like lesions in mice (6), and increases endoplasmic reticulum stress-induced cytokine production by cultured human adipocytes and trophoblasts (16, 17). In addition, increased levels of inflammatory cytokines in response to lipopolysaccharide (LPS) stimulation are seen in the lungs of patients with SERPINA1 deficiency (18). By contrast, treatment with purified SERPINA1 inhibits the production of proinflammatory cytokines in human endometrial cells in vitro (6), and improves the survival rate of mice with peritonitis and sepsis (19). Furthermore, SERPINA1 reduces organ damage in a serine protease activity-independent fashion (17, 18, 20–22). However, the molecular mechanism(s) by which SERPINA1 affects expression of inflammatory factors likely linked to development of endometriotic lesions has not been characterized fully. Here, to investigate the physiological role of SERPINA1 in endometrial stromal cells (ESCs), we extracted RNA from ESCs in which SERPINA1 was knocked down and then performed RNA sequence analysis.

**Materials and methods**

**Cell culture**

Eutopic endometrial tissue samples were collected from patients with endometrioma who were undergoing surgery at Tokyo Medical University Hospital. These patients (n=3) were less than 45 years old and had regular 28–32 day menstrual cycles. Their menstrual phase (Days 16–18; early secretory phase) was identified based on their menstrual history for at least the previous 6 months. All participants provided written informed consent. The study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Clinical Research Ethics Committee of Tokyo Medical University Hospital (approval number: 2017086). Primary cultures of endometrial cells were prepared as previously described (8). In brief, endometrial tissues from the early secretory phase were washed, minced into small pieces, and then digested for 2 h at 37°C by type 1 collagenase (2.5 mg/ml; Sigma-Aldrich, Tokyo, Japan), and DNase I (25 µg/ml; Nippon Gene, Tokyo, Japan). Primary ESCs and Immortalized ESC lines (23) were resuspended in Dulbecco’s modified Eagle’s medium/F12 (DMEM/F12, 1:1; Fujifilm Wako Pure Chemical Corp.) supplemented with 10% fetal bovine serum, antibiotics, and antimitotics. The ESCs were seeded onto culture dishes at 37°C in humidified air containing 5% CO₂, and treated for 24 h with polyinosinic-polycytidylic acid (PIC, a TLR3 agonist; 10 µg/ml; Sigma-Aldrich), a TLR3/dsRNA complex inhibitor (TLR3i; 10 µM; Sigma-Aldrich), LPS (0.2 µg/ml; List Biological Labo., Campbell, CA, USA), TAK-242 (TAK, a TLR4 inhibitor; 10 µM; Selleck Chemicals, Tokyo, Japan), IL-1β (10 ng/ml; Fujifilm Wako Pure Chemical Corp.), or IFN-β (500 ng/ml; Fujifilm Wako Pure Chemical Corp.).

**Transfection of small interfering (si)RNA**

ESCs were transfected with either a non-targeting control, or with SERPINA1 (EHU090971, Sigma-Aldrich), TLR3 (EHU019541, Sigma-Aldrich), or TLR4 siRNA (EHU086621, Sigma-Aldrich) using Lipofectamine RNAiMAX (Thermo Fisher Scientific) (22).
RNA sequencing (RNA-seq), gene ontology (GO), and pathway analyses

RNA-seq analysis was performed with RNA extracted from cultured ESC lines using Isogen II (Nippon Gene). High-throughput sequencing libraries were prepared using a TruSeq Stranded mRNA LT Sample Prep Kit (Illumina, San Diego, CA, USA), according to the manufacturer’s instructions, and data analysis was performed by Macrogen Japan (Kyoto, Japan). Primary sequence data were deposited in the DDBJ (DNA Data Bank of Japan) Sequence Read Archive (https://www.ddbj.nig.ac.jp/dra/index-e.html; accession numbers: DRR304262 to DRR304264 and DRR304268 to DRR304270). Data analysis was performed as described previously (8). Brieﬂy, trimmed sequences were analyzed using the TopHat/Cufflinks pipeline, the human genome (hg38), and reference annotations obtained from the UCSC genome browser (https://genome.ucsc.edu). Signiﬁcantly differentially expressed genes (DEGs) were identiﬁed based on gene-level FPKM (fragments per kilobase of exon per million mapped fragments) expression levels. Genes that had an absolute expression level of >2 FPKM were selected. GO and Enriched Signaling Pathway analyses were performed using the Enrichr tool (http://amp.pharm.mssm.edu/Enrichr/).

RNA extraction and quantitative RT-PCR

RNA was extracted from cultured cells using Isogen II (Nippon Gene), according to the manufacturer’s instructions, and reverse transcribed using a ReverTra Ace qPCR RT Kit (Toyobo, Osaka, Japan). The cDNA produced was then subjected to qPCR amplification using PowerUP SYBR Green Master Mix (Thermo Fisher Scientiﬁc). The primers are listed in Table 1. The ampliﬁcation efﬁciency of each target gene and the reference gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), was measured by calibration curves and found to be comparable. Sequence Detection System software version 2.3 (Thermo Fisher Scientiﬁc) was used to determine the mean crossing threshold (Ct) values for each target (8).

Western blot analysis

Cultured cells were lysed using RIPA buffer (Thermo Fisher Scientiﬁc). The constituent proteins were separated by SDS-PAGE and transferred onto polyvinylidene diﬂuoride membranes (Bio-Rad Laboratories, Hercules, CA, USA) using a trans-Blot Turbo (Bio-Rad). After blocking with Bullet Blocking One (Nacalai Tesque, Inc., Kyoto, Japan), the membranes were incubated with primary antibodies specific for SERPINA1 (1:2,000; Dako, Tokyo, Japan), TLR3 or TLR4 (1:2,000; Proteintech, Tokyo, Japan), MYD88, IRAK1, IRAK4, phosphorylated (p)-IRAK4, IkB, p-IkB, NF-kB, p-NF-kB, IL-1β, COX2, STAT3, JNK, p-JNK, p38, p-p38, ERK1/2, p-ERK1/2 (1:2,000; Cell Signaling Technology, Beverly, MA, USA), MX1 (1:2,000; Sigma-Aldrich), ISG15 (1:2,000; Origene Technologies, Rockville MD, USA), and GAPDH (1:5,000, Fujiﬁlm Wako Pure Chemical Corp.). Immunoreactive bands were detected using an enhanced chemiluminescence kit (Merck Millipore, Burlingame, MA, USA) after incubation with horseradish peroxidase-labeled goat anti-rabbit or anti-mouse IgG (1:5,000; Vector Laboratories, Burlingame, CA, USA). Signals were detected using a C-DiGit Blot Scanner (LI-COR, Lincoln, NE, USA) (22).

Enzyme-linked immunoassay (ELISA)

Culture media were centrifuged at 10,000 × g at 4°C for 10 min and the supernatants were concentrated using a Micron filter device (Amicon ultra-0.5 centrifugal ﬁlter unit; Merck Millipore). The concentrations of IL-1β, IL-6, and IL-8 (encoded by the CXCL8 gene) in the medium were measured using an ELISA kit (Human IL-6 Simple Step ELISA Kit; Abcam, Tokyo, Japan). The concentration of IFN-β in the supernatant was also measured using an ELISA kit (Human IFN-beta Sandwich ELISA kit; Proteintech) (7).

Immunohistochemistry

Endometriotic tissue was obtained from three patients who were undergoing surgery. The protocol was approved by the Clinical Research Ethics Committee of Saitama Medical University and Tokyo University of Pharmacy and Life Sciences (#1512). Parafﬁn sections of endometriotic tissue were immunostained with antibodies targeting TLR3, TLR4, MYD88, E-cadherin, or cytokertatin, according to a previously described protocol (8). Brieﬂy, parafﬁn sections were rehydrated, boiled for 20 min in 10 mM citrate buffer (pH 6.0), and then incubated overnight at 4°C with antibodies speciﬁc for TLR3 (1:200; Proteintech), TLR4 (1:200; Proteintech), MYD88 (1:200; Cell Signaling Technology), E-cadherin (1:200; Cell Signaling Technology), or cytokertatin (1:100; Dako). Subsequently, sections were incubated with Alexa Fluor 568- or 488- labeled alpaca anti-rabbit IgG or anti-mouse IgG2b (Life Technologies Corporation, Carlsbad, CA, USA). Nuclear counterstaining was performed using 4’,6-diamidino-2-phenylindole (DAPI; Life Technologies Corporation). The ﬂuorescently labeled cells were examined under a BZ-X800 microscope (Keyence, Osaka, Japan).
| Name     | Accession No. | Sequence                             | Product length (bp) |
|----------|---------------|--------------------------------------|---------------------|
| GAPDH F: | 5'            | AGCCACATCGTCAGACA                     | -3'                 |
| R: 5'    |               | GCCCAATAGCAGCCAAAATCCC                | -3'                 |
| TLR3 F:  | 5'            | GGCCTAAAATGGAAGAAGACCTGAT            | -3'                 |
| R: 5'    |               | GCTGGAACATTGTTCAAGAAGAGG             | -3'                 |
| NM_003265.3 F: | 5' | CCGTGAGGCATTGAGAGGACTGTA             | -3'                 |
| TLR4 R:  | 5'            | AGTGAGAGGGTGGCTGGTGGCT               | -3'                 |
| NM_138554.5 F: | 5' | GAGGCTGAGAGGCTTTTACAGGG             | -3'                 |
| MYD88 R: | 5'            | GAGGCTGAGAGGCTTTTACAGGG             | -3'                 |
| NM_001172567.2 F: | 5' | GCCCAATACGACCAAATCC                  | -3'                 |
| TLR3 R:  | 5'            | GCCCAATACGACCAAATCC                  | -3'                 |
| NM_001569.4 F: | 5' | CCGCTAAAAAGTGAAGAACTGGAT            | -3'                 |
| IRAK1 R: | 5'            | GCCCAATACGACCAAATCC                  | -3'                 |
| NM_001570.4 F: | 5' | GCTGGACATTGTTCAGAAAGAGG             | -3'                 |
| IRAK2 R: | 5'            | GCTGGACATTGTTCAGAAAGAGG             | -3'                 |
| NM_001572.5 F: | 5' | GCCCAATACGACCAAATCC                  | -3'                 |
| IRF1 R:  | 5'            | GCCCAATACGACCAAATCC                  | -3'                 |
| NM_001565.4 F: | 5' | GCTGGACATTGTTCAGAAAGAGG             | -3'                 |
| IRF2 R:  | 5'            | GCTGGACATTGTTCAGAAAGAGG             | -3'                 |
| NM_001385400.1 F: | 5' | GCCCAATACGACCAAATCC                  | -3'                 |
| IL1B R:  | 5'            | GCCCAATACGACCAAATCC                  | -3'                 |
| NM_002198.3 F: | 5' | GAGGAGGTGAAAGCCTTAGACGCA            | -3'                 |
| IL6 R:   | 5'            | GAGGAGGTGAAAGCCTTAGACGCA            | -3'                 |
| NM_000576.3 F: | 5' | GTAGGAGGGTGAGGAGGATGCG              | -3'                 |
| CXCL8 F: | 5'            | GTAGGAGGGTGAGGAGGATGCG              | -3'                 |
| (NM_000584.4) R:  | 5' | GTAGGAGGGTGAGGAGGATGCG              | -3'                 |
| CXCL10 F: | 5' | GTAGGAGGGTGAGGAGGATGCG              | -3'                 |
| NM_001565.4 F: | 5' | GTAGGAGGGTGAGGAGGATGCG              | -3'                 |
| CXCL11 F: | 5' | GTAGGAGGGTGAGGAGGATGCG              | -3'                 |
| NM_000409.5 F: | 5' | GTAGGAGGGTGAGGAGGATGCG              | -3'                 |
| IL12A F: | 5'            | GTAGGAGGGTGAGGAGGATGCG              | -3'                 |
| NM_000882.4 F: | 5' | GTAGGAGGGTGAGGAGGATGCG              | -3'                 |
| IFNBI R: | 5'            | GTAGGAGGGTGAGGAGGATGCG              | -3'                 |
| NM_001764.4 F: | 5' | GTAGGAGGGTGAGGAGGATGCG              | -3'                 |
| STAT1 R: | 5'            | GTAGGAGGGTGAGGAGGATGCG              | -3'                 |
| NM_007315.4 F: | 5' | GTAGGAGGGTGAGGAGGATGCG              | -3'                 |
| STAT2 F: | 5'            | GTAGGAGGGTGAGGAGGATGCG              | -3'                 |
| NM_005419.4 F: | 5' | GTAGGAGGGTGAGGAGGATGCG              | -3'                 |
| STAT3 F: | 5'            | GTAGGAGGGTGAGGAGGATGCG              | -3'                 |
| NM_139276.3 F: | 5' | GTAGGAGGGTGAGGAGGATGCG              | -3'                 |
| STAT5A F: | 5'            | GTAGGAGGGTGAGGAGGATGCG              | -3'                 |
| NM_012448.4 F: | 5' | GTAGGAGGGTGAGGAGGATGCG              | -3'                 |
| ISG15 F: | 5'            | GTAGGAGGGTGAGGAGGATGCG              | -3'                 |
| NM_005101.4 F: | 5' | GTAGGAGGGTGAGGAGGATGCG              | -3'                 |

(Continued)
Statistical analysis

The qPCR data represent the results of three or more independent experiments, with each sample assayed in triplicate. Data are expressed as the mean ± SEM and were compared using Dunnett’s test in R software (v4.0.5). P < 0.05 was considered statistically significant. In RNA-seq analysis, a false discovery rate-adjusted P-value (q-value) < 0.05 was considered statistically significant (8).

Results

Knockdown of SERPINA1 upregulates expression of TLRs by ESCs

To explore the effect of knocking down SERPINA1 on gene expression in ESCs, we performed RNA-seq analysis. This identified 760 DEGs, of which 337 were downregulated and 423 were upregulated (Figure 1A). KEGG pathway, Wikipathway, and GO enrichment analyses of upregulated genes identified those related to inflammatory-related signals, including "TNF signaling pathway", "Interferon signaling", and "Toll-like receptor signaling pathway" (Figure 1B). The qPCR also revealed an effect of SERPINA1 knockdown on expression of inflammatory-related genes, TLR signaling factors, and interferon stimulated genes (ISGs) in ESCs, which were similar to those measured by RNA-seq analysis (Figure 1C).

TABLE 1

| Name   | Accession No. | Sequence Product length (bp) |
|--------|---------------|------------------------------|
| ISG20  | F: 5'-        | ACACGTCCACTGACAGGCTGTT -3'   | 137 |
|        | R: 5'-        | ATCTTCCACGGAGCTGTGCTCA -3'   |     |
| MX1    | F: 5'-        | GGCCTGTTACCAGACTCCGACA -3'   | 143 |
|        | R: 5'-        | CACAAAGGCTGGCAGCTCTCTTA -3'  |     |
| MX2    | F: 5'-        | AAAACGAGCCGCTGAGGCATG -3'    | 163 |
|        | R: 5'-        | GTGATCCCGGCTGAGGCATG -3'     |     |
| APOBEC3G| F: 5'-       | ATGACACCTGGGCTGAGGCATG -3'   | 114 |
|        | R: 5'-        | GAATCACGTCCAGGAAAGCAGCAG -3' |     |

F, Forward; R, Reverse.

TLR3 upregulates expression of TLR- or inflammatory-related genes in ESCs

To determine whether TLR3 signaling regulated the expression of TLR signaling- and inflammatory-related DEGs in SERPINA1-knockdown ESCs, cells were treated with a TLR3-selective stimulator (PIC) or inhibitor (TLR3i). PIC further increased siSERPINA1-induced expression of MYD88, IRAK4, IRF3, IRF7, IL1B, IL6, CXCL8, and IFNB1 (Figure 2A). By contrast, TLR3i decreased the expression of all these genes, except for MYD88 and IRAK4 (Figure 2A). Furthermore, knockdown of TLR3 using specific TLR3 siRNA decreased siSERPINA1-induced TLR signaling and the expression of inflammatory-related genes in ESCs (Figure 2B). Similar to mRNA expression, siSERPINA1-induced secretion of IL-1β, IL-6, IL-8, and IFN-β by ESCs decreased after TLR3 knockdown (Figure 2C).

TLR4 increases expression of inflammatory-related genes in SERPINA1-silenced ESCs

Similar to TLR3, RNA-seq analysis identified TLR4 as an upregulated DEG in SERPINA1-knockdown ESCs. Therefore, to examine the effect of TLR4 on the expression of TLR signaling- and inflammatory-related factors, cells were treated with a TLR4-selective stimulator (LPS) or inhibitor (TAK). LPS further increased siSERPINA1-induced expression of TLR signaling- and inflammatory-related genes, except for IRF3 (Figure 3A). Conversely, TAK decreased expression of these genes, with the exception of IRF3 and IL6 (Figure 3A). Furthermore, TLR4 knockdown by siRNA decreased siSERPINA1-induced expression of TLR signaling- and
inflammatory-related genes (except IRF3 and IRF7) in ESCs (Figure 3B). Similar to mRNA expression, siSERPINA1-induced secretion of IL-1β and IFN-β by ESCs was decreased by TLR4 knockdown, while the secretion of IL-6 and IL-8 also tended to decrease (Figure 3C).

**IL-1β or IFN-β increases expression of inflammatory-related genes**

To examine whether secreted IL-1β or IFN-β affects ESCs in an autocrine fashion, cells were treated with recombinant IL-1β or IFN-β.
TLR3 upregulates expression of TLR- or inflammatory-related genes in ESCs. (A) Expression of TLR3, TLR4, MYD88, IRAK4, IRF3, IL1B, IL6, CXCL8, and IFNB1 in primary ESCs pre-treated with PIC (10 μg/ml) or TLR3i (10 μM) and then transfected for 24 h with siSERPINA1 (n=3). GAPDH was used as the reference gene. Values represent the mean ± SEM of three independent experiments. *P<0.05, **P<0.01 vs. siSERPINA alone. (B, C) Primary ESCs transfected for 24 h with siSERPINA1 and/or siTLR3. (B) Expression of TLR3, TLR4, MYD88, IRAK4, IRF3, IL1B, IL6, CXCL8, and IFNB1 in primary ESCs (n=3). GAPDH was used as the reference gene. Values represent the mean ± SEM of three independent experiments. *P<0.05, **P<0.01 vs. siSERPINA alone. (C) The culture media were subjected to the ELISA to measure the concentration of IL-1β, IL-6, IL-8, or IFN-β secreted from primary ESCs. Values represent the mean ± SEM of three independent experiments. *P<0.05, **P<0.01 vs. siSERPINA1 alone.
TLR4 increases expression of inflammatory-related genes in SERPINA1-silenced ESCs. (A) Expression of TLR3, TLR4, MYD88, IRAK4, IRF3, IRF7, IL1B, IL6, CXCL8, and IFNB1 in primary ESCs pre-treated with LPS (0.2 μg/ml) or TAK (10 μM) and then transfected for 24 h with siSERPINA1 (n=3). GAPDH was used as the reference gene. Values represent the mean ± SEM of three independent experiments. *P<0.05, **P<0.01 vs. siSERPINA1 alone. (B, C) Primary ESCs transfected for 24 h with siSERPINA1 and/or siTLR4. (B) Expression of TLR3, TLR4, MYD88, IRAK4, IRF3, IRF7, IL1B, IL6, CXCL8, and IFNB1 by ESCs (n=3). GAPDH was used as the reference gene. Values represent the mean ± SEM of three independent experiments. *P<0.05, **P<0.01 vs. siSERPINA1 alone. (C) Culture media were subjected to the ELISA to measure the concentration of IL-1β, IL-6, IL-8, or IFN-β secreted from primary ESCs. Values represent the mean ± SEM of three independent experiments. *P<0.05 vs. siSERPINA1 alone.
or IFN-β. IL-1β further increased siSERPINA1-induced expression of IRF3, IL6, CXCL8, and IFNB1 (Figure 4A). In addition, IFN-β increased siSERPINA1-induced expression of TLR3, TLR4, MYD88, CXCL8, and IFNB1 (Figure 4B).

**TLR3, TLR4, and MYD88 localize at ESCs in endometriosis lesions**

Localization of TLR3, TLR4, and their downstream factor MYD88, was examined in endometriotic lesions using immunohistochemistry. TLR3, TLR4, and MYD88 proteins localized to stromal cells, and to E-cadherin- or cytokeratin-stained glandular epithelial cells (Figure 5).

**Discussion**

The present study is the first to report global transcriptome analysis of SERPINA1-knockdown ESCs. Enrichment analyses of upregulated DEGs revealed that knocking down SERPINA1 affected inflammatory cytokine signaling pathways, including TLRs, IFN, and tumor necrosis factor (TNF). Furthermore, we also noted an increase in the amounts of TLR3 and TLR4 proteins, along with increased expression and phosphorylation of their downstream factors in SERPINA1 knocked-down ESCs. Therefore, we used stimulators, inhibitors, or siRNA to examine the effects of TLR3/4 on expression of inflammatory cytokines and TLR signaling factors MYD88/IRAK4 and IRF3/7 by SERPINA1-silenced ESCs. Treatment with PIC increased...
expression of these factors, whereas a TLR3 inhibitor decreased expression. In addition, siTLR3 reduced secretion of IL-1β, IL-6, IL-8, and IFN-β by ESCs, possibly through downregulation of MYD88/IRAK4 and IRF3/7. Similar to TLR3, the TLR4 agonist LPS increased siSERPINA1-induced expression of TLR signaling- and inflammatory-related genes, whereas a TLR4 inhibitor (TAK) reduced their expression. Furthermore, transfection of siTLR4 reduced secretion of IL-1β and IFN-β. These results indicate that inhibiting expression of siSERPINA1 induces production of inflammatory cytokines via an increase in TLR3/4 proteins, and subsequent activation of their downstream effectors MYD88/IRAK/NF-κB and IRF3/7 (Figure 6).

TLRs are transmembrane proteins comprising three domains: an extracellular domain (responsible for recognition of pathogen-associated molecular patterns (PAMPs)) and danger-associated molecular patterns (DAMPs); a transmembrane domain; and an intracellular domain required for downstream signaling transduction (24, 25). Activation of TLRs triggers a signaling cascade that leads to transcription of numerous genes involved in inflammation and anti-microbial defense. To date, the mammalian family of TLRs comprises 13 members. TLRs 1–9 are conserved between humans and rodents (24, 25). Differences between TLRs include ligand specificity, expression patterns, and activation of different signaling pathways and cellular responses. The endometrium expresses TLRs involved in production of proinflammatory cytokines such as IL-1β. Several studies reported that TLRs may play a role in endometriosis (26). Expression of TLR3/4 in the endometrium of women with endometriosis is higher than that in healthy women (27–33). Furthermore, aberrant TLR activation by DAMPs, which may be induced by oxidative stress and inflammation, during the retrograde menstruation might lead to chronic inflammation and anti-apoptotic responses in endometriotic lesions (26, 34). Our study also found upregulation of TLR3 and TLR4 in SERPINA1-silenced ESCs. Because expression of SERPINA1 is decreased in endometriosis-like lesions in a mouse model, it is possible that TLRs may be involved in inflammatory responses in these lesions. Of note, SERPINA1 knockdown activated TLR3 and TLR4 independently of the treatment with their respective stimulators, as demonstrated by the experiments with TLR3 or TLR4 inhibitors and specific siRNAs. These findings suggest that ESCs in which endometrial SERPINA1 is silenced could induce development and/or exacerbation of endometriosis, independently of microbial/viral infection. However, the molecular mechanisms by which a decrease in SERPINA1 expression upregulates and activates TLR3/4 in ESCs remains unclear; therefore, further investigations are needed to identify the role of SERPINA1 in ESCs.

In the present study, we showed that SERPINA1 knockdown induces inflammatory cytokines such as IL-1β, IL-6, IL-8, and IFN-β through TLR3/4 activation, followed by activation of the
MYD88/IRAK1/4 and IRF3/7 pathways. TLR3/4 regulates several pathways, including MYD88 and TRIF, followed by IRF3/7, MAPKs, and NF-κB, leading to production of cytokines such as IL-1β and IFN-β (26, 35). Recent studies have shown that inflammasomes are involved in intracellular pathways associated with inflammation (36–38). Inflammasomes respond to several PAMPs, including LPS and DAMPs such as uric acid crystals. Nucleotide-binding oligomerization domain-like receptors (NLRs) are intracellular sensors of PAMPs and DAMPs. A representative NLR, NLRP3, is characterized by the presence of a pyrin domain. Activation of NLRP3 promotes its oligomerization, which leads to recruitment and clustering of the inflammasome adapter apoptosis-associated speck-like protein and caspase-1 protease, leading to caspase activation. Activated caspase-1 promotes maturation of IL-1β. COX2 may play an important role in PGE2-mediated activation of the NLRP3 inflammasome (39). Indeed, the NLRP3 inflammasome induces caspase-1 and IL-1β in endometriosis (40, 41). A previous study reported that knockdown of SERPINA1 induces expression of NLRP3, several inflammatory cytokines (IL-1β, IL-6, IL-8), and COX2 in human adipocytes (16). The present study showed that knockdown of SERPINA1 induces IL-1β, and that treatment of ESCs with IL-1β further increases expression of inflammatory cytokines. These findings may imply that silencing stromal SERPINA1 generates IL-1β production in endometriotic lesions via mRNA expression induced by TLRs/MYD88/NF-κB, along with NLRP3 inflammasome-induced caspase-1, all of which may cause a chronic inflammatory response in an autocrine or paracrine fashion.

Our RNA-seq analysis of SERPINA1-knockdown ESCs also identified interferon signaling pathways in addition to inflammatory-related signals. SERPINA1 knockdown increased production of IFN-β via TLR3/4 activation. Notably, TLR3/4 increases production of IFN-β through MYD88 and TRIF signaling (35). Like IL-1β, we examined the possibility that secreted IFN-β affects ESCs in an autocrine or paracrine fashion. Interestingly, we found that IFN-β upregulated TLR3/4 expression in addition to expression of inflammatory cytokines and ISGs. These data suggest that enhanced IFN-β production may upregulate TLR3/4 expression, thereby enhancing TLR3/4 signaling and exacerbating the inflammatory characteristics of endometriosis.

Taken together, the results presented herein suggest that inhibiting expression of SERPINA1 in ectopic ESCs induces expression of inflammatory factors associated with TLR3/4, IL-1β, and IFN-β signaling (Figure 6). Further studies are needed to identify the molecular mechanisms underlying the interaction between SERPINA1 and the TLR3/4, IL-1β, and IFN-β signaling pathways. Such studies might lead to identification of novel treatments for endometriosis.
Data availability statement

The original contributions presented in the study are publicly available. This data can be found here: DNA Data Bank of Japan (DDBJ), Sequence Read Archive (https://www.ddbj.nig.ac.jp/dra/index-e.html). Accession numbers are as followed: DRR304262, DRR304263, DRR304264, DRR304268, DRR304269, DRR304270.

Ethics statement

The studies involving human participants were reviewed and approved by Clinical Research Ethics Committee of Tokyo Medical University Hospital Clinical Research Ethics Committee of Saitama Medical University and Tokyo University of Pharmacy and Life Sciences. The patients/participants provided their written informed consent to participate in this study.

Author contributions

KK and AS contributed to data acquisition. KK and AS contributed to data analysis. MA, MY, YM, and TK prepared tissue sections. MY, JK, MO, and HN isolated primary endometrial stromal cells. KK and KT contributed to study conception, design, and manuscript preparation. All authors contributed to the article and approved the submitted version.

Funding

This research was funded by KAKENHI Grants-in-Aid for Scientific Research [numbers 20H03133 to KK, and 22K09651 to KT] from the Japan Society for the Promotion of Science.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Bulun SE, Yilmaz BD, Sison C, Miyazaki K, Bernardi L, Liu S, et al. Endometriosis. Endocr Rev (2019) 40(4):1048–79. doi: 10.1205/er.2018-00242
2. Gudicke LC, Kao LC. Endometriosis. Lancet (2004) 364(9447):1789–99. doi: 10.1016/S0140-6736(04)17403-5
3. Pullen N, Birch CL, Douglas GJ, Hussain Q, Pruimboom-Brees I, Valley RJ. The translational challenge in the development of new and effective therapies for endometriosis: A review of confidence from published preclinical efficacy studies. Hum Reprod Update (2011) 17(6):791–802. doi: 10.1093/humupd/dmr030
4. Zondevann KT, Becker CM, Koga K, Misserer SA, Taylor RN, Vigano P. Endometriosis. Nat Rev Dis Primers (2018) 4(1):9. doi: 10.1038/s41572-018-0008-5
5. Shiina Hara A, Kutsukake M, Takahashi M, Kyo S, Tachikawa E, Tamura K. Protease-activated receptor-stimulated interleukin-6 expression in endometriosis-like lesions in an experimental mouse model of endometriosis. J Pharmacol Sci (2012) 119(1):40–51. doi: 10.1254/jphs.11216fp
6. Tamura K, Takashima H, Fumoto K, Kajihara T, Uchino S, Ishihara O, et al. Possible role of alpha-antitrypsin in endometriosis-like grafted from a mouse model of endometriosis. Reprod Sci (2015) 22(9):1088–97. doi: 10.1177/1933719115570901
7. Kusama K, Fujikuma Y, Yoshida K, Sakakihara H, Tsubata N, Yoshie M, et al. Endometrial epithelial-mesenchymal transition (Emt) by menstruation-related inflammatory factors during hypoxia. Mol Hum Reprod (2021) 27(6):gaab036. doi: 10.1093/molehr/gaab036
8. Kusama K, Fujikuma Y, Yoshida K, Arumii M, Yoshie M, Mizuno Y, et al. Pg2 and thrombin induce myofibroblast transdifferentiation via activin a and ctgf in endometrial stromal cells. Endocrinology (2021) 162(12):gobah207. doi: 10.1210/endocr/gobah207
9. Othman Eel D, Hornung D, Salem HT, Khalifa EA, El-Metwally TH, Al-Handy A. Serum cytokines as biomarkers for nonsurgical prediction of endometriosis. Eur J Obstet Gynecol Reprod Biol (2008) 137(2):240–6. doi: 10.1016/j.ejogrb.2007.05.001
10. Sikora J, Smycz-Kubanska M, Mielczarek-Palace A, Kondera-Anna Z. Abnormal peritoneal regulation of chemokine activation-the role of il-8 in pathogenesis of endometriosis. Am J Reprod Immunol (2017) 77(4):e12622. doi: 10.1111/aji.12622
11. Di Leon FD, Vijayakumar R, Rao CV, Yussman M. Prostaglandin F2 alpha and E2 release by peritoneum with and without endometriosis. Int J Fertil (1988) 33(1):48–51.
12. Liu Y, Hu J, Shen W, Wang J, Chen C, Han J, et al. Peritoneal fluid of patients with endometriosis promotes proliferation of endometrial stromal cells and induces cox-2 expression. Fertil Steril (2011) 95(5):1836–8. doi: 10.1016/j.fertnstert.2010.11.039
13. Lucidi R, Witz CA, Chrico M, Binkley PA, Shain SA, Schenken RA. A novel in vitro model of the early endometriotic lesion demonstrates that attachment of endometrial cells to mesothelial cells is dependent on the source of endometrial cells. Fertil Steril (2005) 84(1):16–21. doi: 10.1016/j.fertnstert.2004.10.058
14. Maybin JA, Critchley HO, Jabbour HN. Inflammatory pathways in endometrial disorders. Mol Cell Endocrinol (2011) 335(1):42–51. doi: 10.1016/j.mce.2010.08.006
15. Hunt JM, Tuder R. Alpha 1 anti-trypsin: One protein, many functions. Curr Mol Med (2012) 12(7):827–35. doi: 10.2174/156652412801318755
16. Ando Y, Kuroda A, Kusama K, Matsutani T, Matsuda A, Tamura K. Impact of serine protease inhibitor alpha-1-antitrypsin on expression of endoplasmic reticulum stress-induced proinflammatory factors in adipocytes. Biochem Biophys Res (2021) 26:10967. doi: 10.1016/j.bbrep.2021.10967
17. Yoshida K, Kusama K, Fujikuma Y, Ohtsuru-Nakanishi T, Kato K, Tamura K. Alpha-1 antitrypsin-induced endoplasmic reticulum stress promotes invasion by extravillous trophoblasts. Int J Mol Sci (2021) 22(7):3683. doi: 10.3390/ijms22073683
Kusama et al.

18. Jonigk D, Al-Omari M, Maegel L, Muller M, Izykowski N, Hong J, et al. Anti-inflammatory and immunomodulatory properties of Alpha-1-antitrypsin without inhibition of elastase. *Proc Natl Acad Sci USA* (2011) 110(37):15007–12. doi: 10.1073/pnas.1009648110

19. Kaner Z, Ochayon DE, Shahaf G, Baranzovski RM, Bahar N, Mizrahi M, et al. Acute phase protein Alpha1-antitrypsin reduces the bacterial burden in mice by selective modulation of innate cell responses. *J Infect Dis* (2015) 211(9):1489–98. doi: 10.1093/infdis/jtu20

20. Gou W, Wang J, Song L, Kim DS, Cui W, Strange C, et al. Alpha-1 antitrypsin suppresses macrophage activation and promotes islet graft survival after intrahepatic islet transplantation. *Am J Transplant* (2021) 21(3):1713–24. doi: 10.1111/ajt.16342

21. Pott GB, Chan ED, Dinarello CA, Shapiro L. Alpha-1-Antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood. *J Leukoc Biol* (2009) 85(5):886–95. doi: 10.1189/jlb.0208145

22. Yoshida K, Yano A, Kusama K, Ishikawa G, Tamura K. Alpha 1 antitrypsin regulates trophoblast syncytialization and inflammatory factor expression. *Int J Mol Sci* (2022) 23(4):1995. doi: 10.3390/ijms23041955

23. Tamura K, Yoshie M, Haru T, Isaka K, Kogo H. Involvement of statin in proliferation and differentiation of immortalized human endometrial stromal cells. *J Reprod Dev* (2007) 53(3):525–33. doi: 10.1226/jrd.18129

24. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. *Cell* (2006) 124(4):783–801. doi: 10.1016/j.cell.2006.02.015

25. Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. *Cell Death Discov* (2015) 110(37):15007. doi: 10.1111/ajj.12425

26. de Azevedo BC, Mansur F, Podgaec S. A systematic review of toll-like receptors in innate immunity. *Cell Death Discov* (2015) 110(37):15007. doi: 10.3892/cddiscovery.2016.19

27. Almassi MZ, Hosseini E, Jafari R, Aghajanpour S, Ramazanali V, Atchoonian K, Aghajanpour S, Ramazanali F, et al. Evaluation of toll-like receptor 3 (TLR3) signaling pathway genes and its genetic polymorphisms in atopic and eutopic endometrium of women with endometriosis. *J Gynecol Obstet Hum Reprod* (2022) 50(9):20153. doi: 10.1016/j.jogoh.2021.102153

28. Hayashi C, Chishima F, Sugitani M, Ichikawa G, Nakazawa-Watanabe T, Sugita K, et al. Relationships between toll-like receptor-4 and mpeg1-gene expression in local lesions of endometriosis patients. *Am J Reprod Immunol* (2013) 69(3):231–9. doi: 10.1111/aji.12056

29. Khan KN, Kitajima M, Hiraki K, Fujishita A, Sekine I, et al. Toll-like receptor-4-mediated growth of endometriosis by human heat-shock protein 70. *Hum Reprod* (2008) 23(10):2210–9. doi: 10.1093/humrep/den195

30. Khan KN, Kitajima M, Hiraki K, Yamaguchi N, Katamine S, Matsuyama Y, et al. Escherichia coli contamination of menstrual blood and effect of bacterial endotoxin on endometriosis. *Fertil Steril* (2010) 94(7):2860–3 e1–3. doi: 10.1016/j.fertnstert.2010.04.053

31. Khan KN, Kitajma M, Inamura T, Hiraki K, Fujishita A, Sekine I, et al. Toll-like receptor-4-mediated growth of endometriosis by human heat-shock protein 70. *Hum Reprod* (2008) 23(10):2210–9. doi: 10.1093/humrep/den195

32. Khan KN, Kitajima M, Inoue T, Tateishi S, Fujishita A, Nakashima M, et al. Additive effects of inflammation and stress reaction on toll-like receptor-4-mediated growth of endometriotic stromal cells. *Hum Reprod* (2013) 28(10):2794–803. doi: 10.1093/humrep/det280

33. Luo XZ, Zhou WJ, Tao Y, Wang XQ, Li DJ. TLR4 activation promotes the secretion of IFN-γ which enhances the invasion and proliferation of endometrial stromal cells in an autocrine manner via the fak signal pathway. *Am J Reprod Immunol* (2015) 74(6):467–79. doi: 10.1111/ajr.12425

34. Kobayashi H, Higashiura Y, Shigetomi H, Kajibara H. Pathogenesis of endometriosis: The role of initial infection and subsequent sterile inflammation (Review). *Mol Med Rep* (2014) 9(1):9–15. doi: 10.3892/mmr.2013.1755

35. Yamamoto M, Sato S, Hennmi H, Hoshino K, Kisho T, Sanjo H, et al. Role of adaptor trf in the Myd88-independent toll-like receptor signaling pathway. *Science* (2003) 301(5633):640–3. doi: 10.1126/science.1087262

36. Coll RC, O'Neill L, Schroder K. Questions and controversies in innate immunity research: What is the physiological role of Nlrp3? *Cell Death Differ* (2016) 230(4):863–74. doi: 10.1038/cddiscovery.2016.19

37. Guo H, Callaway JB, Ting JP. Inflammosomes: Mechanism of action, role in disease, and therapeutics. *Nat Med* (2015) 21(7):677–87. doi: 10.1038/nm.3893

38. Lamkanfi M, Dixit VM. Mechanisms and functions of inflammasomes. *Cell* (2014) 157(5):1013–22. doi: 10.1016/j.cell.2014.04.007

39. Hua XE, Chou IC, Ka SM, Tsai YL, Chen A, Wu SH, et al. Cyclooxygenase-2 regulates Nlrp3 inflammasome-derived IL-1beta production. *J Cell Physiol* (2015) 230(4):863–74. doi: 10.1002/jcp.24815

40. Hang Y, Tan L, Chen Q, Liu Q, Jin Y. E3 ubiquitin ligase Trim24 degrades TRAF2 and promotes Nlrp3/Caspase-1/Il-1beta-Mediated pyroptosis in endometriosis. *Hum Reprod* (2013) 28(10):2794–803. doi: 10.1093/humrep/det280

41. Sikora J, Mielczarek-Palacz A, Kondera-Anasz Z. Association of the precursor of interleukin-1beta and peritubal inflammation-role in pathogenesis of endometriosis. *J Clin Lab Anal* (2016) 30(6):831–7. doi: 10.1002/jcla.21944